Adar1 Capital Management, LLC Portfolio Holdings

Adar1 Capital Management, LLC

  • $652 Billion
  • Q2 2025

Adar1 Capital Management, LLC has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $652 Billion distributed in 210 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Keros Therapeutics, Inc. with a value of $71.9B, Protagonist Therapeutics, Inc with a value of $52.4B, Ea Series Trust with a value of $38B, Zai Lab LTD with a value of $29.7B, and Abivax Sa with a value of $23.5B.

Examining the 13F form we can see an increase of $113B in the current position value, from $539B to 652B.

Adar1 Capital Management, LLC is based out at Austin, TX

Below you can find more details about Adar1 Capital Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $652 Billion
Healthcare: $418 Billion
ETFs: $56.4 Billion
Basic Materials: $135 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$353M
$71.9 Billion 11.03% of portfolio
5,389,264
Q2 2025 Added 262.56%
$2.68B
$52.4 Billion 8.04% of portfolio
948,069
Q2 2025 Added 0.89%
Ea Series Trust
-
$38 Billion 5.83% of portfolio
-
Q1 2025 Added 3.59%
$3.36B
$29.7 Billion 4.56% of portfolio
850,437
Q2 2025 Reduced 9.61%
Abivax Sa
-
$23.5 Billion 3.6% of portfolio
-
Q2 2025 Added 38.97%
$8.15B
$21.9 Billion 3.35% of portfolio
1,940,797
Q2 2025 Reduced 44.28%
$354M
$20.5 Billion 3.14% of portfolio
3,375,009
Q2 2025 New
$3.23B
$19.2 Billion 2.95% of portfolio
582,147
Q2 2025 Added 48.99%
$0
$14 Billion 2.15% of portfolio
22,684
Q2 2025 New
Cg Oncology Inc
-
$13.6 Billion 2.09% of portfolio
-
Q2 2025 Added 73.75%
$0
$12.4 Billion 1.91% of portfolio
135,585
Q1 2025 Added 2.88%
$7.28B
$11.2 Billion 1.72% of portfolio
259,659
Q2 2025 Reduced 23.55%
Inhibikase Therapeutics Inc
-
$9.99 Billion 1.53% of portfolio
-
Q1 2025 Added 0.37%
Septerna Inc
-
$8.96 Billion 1.37% of portfolio
-
Q2 2025 Added 17.53%
$510M
$8.73 Billion 1.34% of portfolio
2,825,773
Q2 2025 Added 50.38%
$420M
$8.6 Billion 1.32% of portfolio
875,983
Q2 2025 Added 8.92%
$294M
$8.21 Billion 1.26% of portfolio
3,600,670
Q2 2025 Added 164.7%
$2.24B
$8.12 Billion 1.25% of portfolio
259,503
Q2 2025 Added 103.46%
Bioage Labs Inc
-
$8 Billion 1.23% of portfolio
-
Q2 2025 Added 99.48%
Perceptive Cap Solutions Cor
-
$7.97 Billion 1.22% of portfolio
-
Q2 2024 New
$481M
$7.72 Billion 1.18% of portfolio
1,205,101
Q2 2025 Reduced 18.11%
$141M
$6.95 Billion 1.07% of portfolio
3,009,870
Q2 2025 Added 182.27%
$123M
$6.99 Billion 1.07% of portfolio
3,081,414
Q2 2025 Added 6,451.18%
$516M
$6.58 Billion 1.01% of portfolio
721,599
Q2 2025 Reduced 2.81%
Rapt Therapeutics Inc
-
$6.27 Billion 0.96% of portfolio
-
Q2 2025 New
Aa Mission Acquisition Corp
-
$6.03 Billion 0.92% of portfolio
-
Q1 2025 Added 3.24%
$5.85B
$5.87 Billion 0.9% of portfolio
148,461
Q2 2025 New
$18.4B
$5.8 Billion 0.89% of portfolio
345,878
Q2 2025 Reduced 33.96%
Oaktree Acquisition Corp Iii
-
$5.48 Billion 0.84% of portfolio
-
Q1 2025 Added 3.3%
$667M
$5.27 Billion 0.81% of portfolio
469,018
Q2 2025 New
$3.09B
$4.93 Billion 0.76% of portfolio
134,136
Q2 2025 Reduced 24.28%
Helix Acquisition Corp Ii
-
$4.7 Billion 0.72% of portfolio
-
Q2 2025 Reduced 5.77%
$0
$4.42 Billion 0.68% of portfolio
53,337
Q2 2025 Reduced 48.39%
$241M
$4.41 Billion 0.68% of portfolio
989,297
Q2 2025 Reduced 11.36%
Bridgebio Pharma Inc
-
$4.19 Billion 0.64% of portfolio
-
Q4 2024 New
Mineralys Therapeutics Inc
-
$4.09 Billion 0.63% of portfolio
-
Q2 2025 Added 14.69%
$1.61B
$3.9 Billion 0.6% of portfolio
296,766
Q2 2025 Added 37.29%
$1.6B
$3.6 Billion 0.55% of portfolio
210,313
Q2 2025 Added 71.1%
Monopar Therapeutics Inc
-
$3.61 Billion 0.55% of portfolio
-
Q2 2025 Added 0.2%
$866M
$3.59 Billion 0.55% of portfolio
915,130
Q2 2025 Added 86.48%
$217M
$3.38 Billion 0.52% of portfolio
622,873
Q2 2025 Added 522.87%
$1.78B
$3.19 Billion 0.49% of portfolio
98,032
Q2 2025 Added 665.88%
$5.51B
$2.87 Billion 0.44% of portfolio
45,390
Q2 2025 Added 23.04%
$6.41B
$2.69 Billion 0.41% of portfolio
28,450
Q2 2025 Added 42.25%
Bridgebio Pharma Inc
-
$2.49 Billion 0.38% of portfolio
-
Q4 2024 New
$165M
$2.41 Billion 0.37% of portfolio
1,723,526
Q2 2025 Added 353.17%
$717M
$2.38 Billion 0.37% of portfolio
170,598
Q2 2025 Added 115.95%
A Spac Iii Acquisition Corp
-
$2.2 Billion 0.34% of portfolio
-
Q1 2025 New
$474M
$2.16 Billion 0.33% of portfolio
175,000
Q2 2025 New

Summary

  • Portfolio
  • No. of Stocks 210
  • Current Value $652 Billion
  • Prior Value $539 Billion
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 43 stocks
  • Additional Purchases 61 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 53 stocks
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email